CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 27 enrolled
Drug / intervention
LY2606368drug
Likely dose
Not stated in record
Key inclusion· 8
  • ✓Pathologically confirmed advanced solid tumor without effective standard therapy
  • ✓Confirmed genomic abnormality indicative of replicative stress: MYC amplification, CCNE1 amplification, Rb loss, FBXW7 mutation, or other agreed abnormality
  • ✓Confirmed HR deficiency: mutation in BRCA1, BRCA2, PALB2, RAD51C, RAD51D, ATR, ATM, CHK2, Fanconi anemia pathway genes, or other known HR gene
  • ✓CCNE1 cohort: CCNE1 amplification of 6-fold or greater (borderline levels may be considered with PI approval)
Key exclusion· 8
  • ✕Prior treatment with a CHK1 inhibitor
  • ✕Untreated brain metastases (treated/stable metastases ≥1 month off corticosteroids are permitted)
  • ✕Personal or family history of long QT syndrome
  • ✕History of allergic reactions to compounds of similar chemical or biologic composition to LY2606368

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02873975
NCT02873975Phase 2Completed
CompareCT.gov

A Phase II Study of the CHK1 Inhibitor LY2606368 in Patients With Advanced Solid Tumors Exhibiting Replicative Stress or Homologous Recombination Repair Deficiency

Dana-Farber Cancer Institute·interventional·Posted Aug 22, 2016·Updated Oct 21, 2022

In Brief

A Phase 2 clinical trial evaluating LY2606368 for Advanced Cancers. Completed, enrolled 27 participants across 1 site.

Detailed Summary

This research study is studying a checkpoint kinase 1 (CHK1) inhibitor as a possible treatment for advanced solid tumors that harbor genetic alterations in the homologous repair (HR) pathway, genetic alterations that indicate replication stress, or with CCNE1 amplification.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Cancers
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 22, 2016
Enrollment StartOct 12, 2016
Primary CompletionSep 30, 2020
Study CompletionJul 1, 2021
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 9.9 years ago

Interventions

LY2606368drug